King Khalid University researchers also report substantial weight regain after people stop the drug, and flag gallbladder and retinopathy signals worth watching.
Recap by typeshit. Full story at BIOENGINEER.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
A TriNetX study of 4,253 matched patients per group, shown at ACG 2026, found roughly half the MACE risk at one year with resmetirom. Retrospective data, so no causation.
Compounds modeled on the weight loss blockbusters are also in trials for schizophrenia and Parkinson's disease, among other brain conditions.
Loading…